Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; lactose monohydrate; magnesium stearate - indications as at 22 october 2003: treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; microcrystalline cellulose; sodium starch glycollate - indications as at 22 october 2003: treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - oryzalin - suspension concentrate - oryzalin anilide/aniline-dinitro active 500.0 g/l - herbicide - almond | amenity plantings | apple | apricot | banana | cherry | conifer - seedling stage | grape | grapefruit | macadamia nut | - barnyard grass or water grass | barnyard or water grass | blackberry nightshade | caltrop or yellow vine | deadnettle | fat hen | fumitory | guinea grass | lovegrass | paddy melon | paradoxa grass | pigeon grass | pigweed spp. | silverleaf nightshade | sow or milk thistle | spiny burrgrass, innocent weed | summer or crab grass | wireweed, knotweed or hogweed | annual lovegrass | annual phalaris | annual pigweed | annual summer grass | barnyard grass | bindy-eye | black nightshade | bullhead | bull's head | caltrop burr | canary grass | cathead | cat's-head | common sowthistle | fallopia aviculare | gentle annie | goat's-head | gooseberry melon | hedgehog grass | henbit deadnettle | munyeroo | nightshade | pigeon weed | pink weed | portulaca oleracea | prickly paddy melon | puncture vine | purple pigeon grass | purslane | setaria gracilis | setaria pallidefusca | setaria porphyrantha | setaria pumila | setaria verticillata | setaria viridis | silver-leaf nightshade | sow thistle | sowthistle | stingless nettle

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - pravastatin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - clozapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium cromoglycate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - nevirapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose; sodium stearylfumarate; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. cholvastin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. cholvastin is indicated in patients with unstable angina pectoris see clinical trials). 4. cholvastin is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials). 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. vastoran is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. vastoran is indicated in patients with unstable angina pectoris see clinical trials). 4. vastoran is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose; sodium stearylfumarate; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. cholvastin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. cholvastin is indicated in patients with unstable angina pectoris see clinical trials). 4. cholvastin is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials). 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. vastoran is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. vastoran is indicated in patients with unstable angina pectoris see clinical trials). 4. vastoran is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - nevirapine -